You are here
In this Section
- Office of the Scientific Director
- Office of the Clinical Director
- NIAAA Laboratories
- Laboratory of Behavioral & Genomic Neuroscience
- Laboratory of Cardiovascular Physiology and Tissue Injury
- Laboratory for Integrative Neuroscience
- LIN - Office of the Chief
- LIN - Section on Neuronal Structure
- LIN - Section on Synaptic Pharmacology (SP)
- Laboratory of Liver Diseases
- Laboratory of Metabolic Control
- Laboratory of Molecular Signaling
- Laboratory of Molecular Physiology
- Laboratory of Membrane Biochemistry and Biophysics
- Laboratory of Neurogenetics
- Laboratory for Neuroimaging
- Laboratory of Physiologic Studies
- Chemical Biology Research Branch (joint lab with NIDA)
- Clinical NeuroImaging Core
- Section on Clinical Genomics and Experimental Therapeutics (CGET)
- Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)
- Section on Human Psychopharmacology (HP)
- Office of Laboratory Animal Science (OLAS)
- Join a Study - Clinical Research
- DICBR Organization Chart
Office of the Clinical Director
The OCD’s main purposes are to ensure patient safety and confidentiality, monitor regulatory compliance, assist in policy and resource management, foster training and education, and facilitate the work of intramural clinical investigators. The specific functions of the OCD include:
1) Providing oversight of patient care and patient-related activities within the Division of Intramural Clinical and Biological Research (DICBR), including quality assurance, quality improvement, and human subject protections, thereby ensuring safety and confidentiality
2) Guaranteeing that physicians and other staff not limited to nurse practitioners, physician assistants, clinical social workers, nurses, and clinical psychologists have the required licensing, certification, and credentialing through NIH Clinical Research Center (CRC) and are otherwise appropriately qualified for their clinical contacts with patients
3) Assisting the Scientific Director in allocating NIAAA and NIH CRC resources including Clinical Center Unit space, Clinical Center Office space, and Clinical Center Clinic space assigned to NIAAA and other CRC-administered resources including neuroimaging, clinical pathology, and pharmacy
4) Supporting Fellowship programs and training and career development of OCD staff
In addition to the above functions, the OCD conducts clinical research, including development and implementation of clinical research protocols and research initiatives; monitors NIAAA protocol review through NIH Institutional Review Boards (IRBs); delivers clinical and administrative infrastructure for NIAAA clinical research protocols as well as basic science studies involving clinical specimens; and assists the Scientific Director in strategic planning that focuses on new clinical research opportunities including studies informed by neurobiology, novel approaches to treatments, comorbidity with other diseases, and design of clinical trials. Furthermore, the OCD creates opportunities for young physician scientists in alcohol research by developing programs for training in addictions medicine.
David Goldman, M.D.
Dr. David Goldman has been Chief of the Laboratory of Neurogenetics since 1991 and is Acting Clinical Director of NIAAA. Dr. Goldman graduated cum laude from Yale University and magna cum laude from the University of Texas Medical Branch, Galveston where he was also a Resident in Psychiatry. He joined NIAAA in 1979, was an NIMH Clinical Associate 1980-1984, and rejoined NIAAA in 1985. He is a Fellow of the American College of Neuropsychopharmacology. Throughout his career, Dr. Goldman has focused on identifying genes that influence vulnerability to alcoholism, other addictions and other psychiatric diseases. He has authored over 400 papers, including several of the first “imaging genetics” studies in which genes were shown to alter brain function. He and his group have used various complex methods to explore genetics, and he has discovered inherited gene variations that alter function of molecules in the body and has traced the effects of these genetic variations through to complex behaviors in both humans and animal models. His studies have also taken advantage of the ability to control genetic and environmental factors in animal models, both for gene discovery and for validation of gene effects. Dr. Goldman won the James Isaacson Research Award of the International Society for Biological Research on Alcoholism and twice won the NIH Director’s Award. He is author of “Our Genes, Our Choices,” which won The British Medical Association top prize.
Nancy Diazgranados, M.D., M.S.
Deputy Clinical Director
Dr. Diazgranados received her Doctoral Degree in Medicine and Surgery from the Pontificia Universidad Javeriana in Bogota Colombia in 2001. She completed her Psychiatry residency at Albert Einstein Medical Center and a Master in Science Degree in Pharmacology at Thomas Jefferson University in 2007. In 2008 she became a diplomate of the American Board of Psychiatry and Neurology. She continued her training as a Post-Doctoral Clinical-Research Fellow at the intramural program at NIMH; there she worked at the Experimental Therapeutics and Pathophysiology Branch in the Mood and Anxiety Disorders Program. In 2010 she joined the University of Texas Health Science Center at San Antonio as a tenure track assistant professor within the Division of Mood and Anxiety Disorders. In 2012 she relocated to Maryland and started a private practice. Dr. Diazgranados is a Fellow of the American Psychiatric Association and a recipient of multiple research awards. She joined NIAAA in September, 2013 where she now serves as Deputy Clinical Director in the intramural program.
Clinical Operations Manager
Originally from Kingston, Jamaica, Janet’s family migrated to Brooklyn, New York once they arrived in the United States. She attended Saint Peter’s University in Jersey City, NJ, from which she received her Bachelor of Science degree in Business Management. After graduation she worked as a Litigation Paralegal with a prominent business law firm, including relocation to Washington, DC. After leaving the law firm she worked as an Executive Assistant to the Education Executive Director for the American Physiological Society for about 4 years. Then she worked in the Office of the Director as an Executive Assistant to the Deputy Director for the Center for Scientific Review within the National Institutes of Health for about 4 years. Before returning back to NIH within the Office of the Clinical Director for National Institute of Alcohol Abuse and Alcoholism she worked at the Medicaid and CHIP Payment and Access Commission (MACPAC) assisting the founding Executive Director.
Protocol Coordinator and Monitor
Betsy Davis serves the OCD as a protocol coordinator/monitor. She has an extensive background in clinical research. Betsy has been involved in many and varied studies since joining the Institute in 1980, including neuropsychological testing of patients with Alcohol Amnestic Disorder and Alcoholic Dementia, studies of electroencephalography and evoked potentials and work with both PET and MRI studies. She has been responsible for all aspects of running many of these studies, from advertisement, patient recruitment and screening to testing the subjects, entering data and analysis. Having been responsible for so many aspects of running clinical protocols in the past has helped to prepare Betsy for her role as coordinator/monitor. In addition to monitoring, she works on the programming of data collection instruments for computer administration of self-report questionnaires. She also participates in the training of staff in procedures and processes related to GCP compliance and computerized testing.
David T. George, M.D.
Dr. George is a senior scientist in the NIAAA OCD. Dr. George received his Medical Degree from Bowman Gray School of Medicine of Wake Forest University. He has completed residencies in Internal Medicine at Henry Ford Hospital, Detroit, Michigan and in Psychiatry at Duke University, Durham, North Carolina. He is board certified in both internal medicine and psychiatry. His major research interests include exploring new treatments for alcoholism and understanding the biological antecedents of domestic violence and PTSD. He has published more than 100 peer reviewed articles and is the author of Untangling the Mind. Why We Behave the Way We Do. Dr. George is a Clinical Professor at George Washington University School of Medicine.
Adria Gray, M.S.
Adria is the Patient Coordinator for NIAAA. Adria received her Bachelor’s in Psychology from George Mason University also minoring in Conflict Analysis and Resolution. Adria went on to complete her Master’s at Walden University in Mental Health Counseling. Adria’s background includes residential settings and private practice engaging in crisis management and therapeutic interventions. She aspires to become an Art Therapist and continue progressing within multiple areas of the field currently exploring substance use.
Since joining NIAAA in November 1979, Cheryl has had several titles, roles, and responsibilities. Currently, her responsibilities include a combination of study data coordination and management, training, and quality assurance (QA) monitoring. She is responsible for independent quality assurance review of patient safety data and eligibility criteria for three active investigational drug protocols. This involves reviewing each patient’s case report form (CRF), eligibility, labs, and source documents. Following the monitoring of completed CRFs, she reports protocol deviations and irregularities, correction requests, and corrective actions to the PI. In addition to her other duties, she reviews and records auditory stimuli for stress challenge studies. She also attends monthly inter-institute QA advisory committee (IRPAC) meetings as well as the LCTS/IT group data management monthly meetings. Cheryl holds a B.A. in Family Living and Human Development from the University of the District of Columbia.
Tim Klepp, B.A.
Postbaccalaureate Intramural Research Training Awardee (IRTA)
Tim Klepp works in both the OCD and the Section on Human Psychopharmacology. He started his work with the NIAAA shortly after completing his B.A. in Medical Ethics with a minor in Chemistry from New York University in May 2015. In his undergraduate research at the FDA, he conducted flow cytometric analysis of PBMC samples in an effort to develop biomarkers for allergic reactions to metals used in joint implants. He is currently responsible for administering cognitive and behavioral testing of subjects and management of data collection with the OCD. As part of his work with LCTS, Tim assists with a PET study on the effects of morphine and is also working on a project analyzing lipid profiles in heavy drinkers. He is interested in the interaction between mood disorders and substance dependence, and their impact on metabolic processes. He plans to pursue these interests in medical school.
Hiroshi Sakuma, M.D., Ph.D.
Dr. Sakuma is a volunteer researcher in the OCD. He is presently engaged in research on alcohol response and identifying phenotypes of Alcohol Use Disorder (AUD). Dr. Sakuma started his career as a researcher and a clinical psychiatrist. He received his M.D. in 1995 from the Fukushima Medical University in Japan. He majored in psychiatry and received his Ph.D. in Medical Science in 2011 at Fukushima Medical University in Japan, where he conducted neuropsychological research about cognitive dysfunctions in Schizophrenia. Dr. Sakuma worked in Kurihama Medical and Addiction Center as a chief of psychiatry since 2012. While there, his research included studies on the epidemiology of addictive behavior after the Great East Japan Earthquake in 2011, Internet Addiction therapeutic camp program (a collaboration with the Ministry of Education, Culture, Sports, Science and Technology in Japan), and development and assessment of an Anger Management Program focused on AUD.
Clinical Core Laboratory
Dr. Damadzic joined the Laboratory of Clinical and Translational Studies, NIAAA, in October 2006 after finishing postdoctoral training and employment in NIMH. He received his M.D. degree in University of Tuzla, Bosnia and Herzegovina, where he completed Internship and General Practice training. Dr. Damadzic came to NIMH as a Fogarty Fellow awardee, working in the Clinical Brain Disorders Branch and investigating several projects in neuroanatomical study in human adults with schizophrenia, bipolar disorder, and unipolar depression. He continued his training in NIMH where he worked on study on the PACAP effect. His group discovered that PACAP might act to protect the brain from paraphysiological insult, including exposure to toxins or hypoxia. In last several years in LCTS/NIAAA, as a neuroanatomist and biologist, he began work with a research team to better understand the consequences of excessive ethanol consumption on the brain and behavior and assisted in development of new pharmacotherapeutics. His research efforts focus on understanding the brain’s biological changes that lead to excessive alcohol consumption and the neurochemical changes that occur with alcohol addiction.
Clinical Training Programs
NIH Office of Human Subjects Research Protections/Human Research Protections Program (OHSRP/HRPP):
NIH OHSRP/HRPP Standard Operating Procedures (SOP):
| Back to Top |